Disease Info Card

Histiocytoma, Benign Fibrous

Information about Histiocytoma, Benign Fibrous: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Histiocytoma, Benign Fibrous

Most recent studies have shown that Histiocytoma, Benign Fibrous shares some biological mechanisms with angiofibroma, bone-neoplasms, carcinoma, cutaneous-fibrous-histiocytoma, fibrosarcoma, histiocytoma, leiomyosarcoma, liposarcoma, lung-neoplasms, malignant-fibrous-histiocytoma, malignant-neoplasms, malignant-paraganglionic-neoplasm, nasopharyngeal-neoplasms, neoplasm-metastasis, neoplasm-recurrence-local, neoplasms, osteosarcoma, sarcoma, skin-neoplasms, soft-tissue-neoplasms.

Among the many pathways, these few ones have gauged particular interests from scientists studying Histiocytoma, Benign Fibrous, and have been seen in publications frequently: Angiogenesis, Cell Adhesion, Cell Cycle, Cell Death, Cell Differentiation, Cell Growth, Cell Proliferation, Coagulation, Dedifferentiation, Enucleation, Immune Response, Induction Of Apoptosis, Localization, Mitosis, Pathogenesis, Phagocytosis, Pigmentation, Secretion, Wound Healing

Quite a number of genes have been found to play important roles in Histiocytoma, Benign Fibrous, such as CD34, CD68, CTLA4, DES, F13A1, HLA-DQA1, KIT, LYZ, MME, MUC1, NOD2, S100A1, S100B, SERPINA1, SERPINA3, TNF, TP53, VIM. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.